The domestic launch of the stomach cancer target agent ‘Cyramza’ is visualized

Published: 2015-04-17 14:00:57

Updated: 2015-04-17 14:00:57

The fact that a new target agent for stomach cancer is visualized attracted the pharmaceutical industry.

According to the Ministry of Food and Drug Safety on the 15^th, the Lilly Korea’s stomach cancer target agent ‘Cyramza(ramucirumab)’ has been approved.

Cyramza can be used as a solo therapy and a joint therapy for progressive and metastatic stomach or gastroesophageal junction adenocarcinom...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.